Figure 2 Example configurations of healthcare Chips.

Marks describes the world of the “new possible,” where everyone becomes a productiser making products, where owners become true influencers, and where some, like the ‘super subs’, general contractors, and builders, become systems integrators.In this space, she says, it is only the architects who become more fully what they’ve always been and always set out to be..

In this new world, she says, the architects will “truly become empowered architects, when you actually put real things in their hands…”.Johnston, an architect himself, is keen to reclaim the role.He feels these new tools will help architects improve designs, outcomes and generally “achieve better things for clients.”.

In other words, it’s the combination of productisation and technology that becomes the truly enabling factor..Currently, Marks says, “we're letting people design with things that aren't real, and we're letting them make them less real by stretching them, or only looking at geometric shapes.

You actually need discrete data, you need the connection with the maker as the architect.

In order to set the right parameters you need generative design, you need multi-dimensional CAD like Revit, you need those things in order to make the right decisions.”.over the lifetime of a portfolio of products.

and where there appears to be little impact..It is also worth saying that the results have not been modelled where there are lower risk profiles than those of bringing new pharmaceutical products to market.. Let me start with a first curve.. M. odelled.

a scenario where the revenue value of the new products was very high.you can see that scale has little relative influence over the NPV at different scales.